Navigation Links
ChanTest to Highlight Expanded Ion Channel and GPCR Services and Cell Lines, Including FDA Critical Path Safety Profiling Tools at ToxExpo, Booth 3056
Date:3/10/2009

- Company to host seminar Tuesday, March 17, 2009, from 8:30 to 9:30 AM in Room 337

CLEVELAND, Ohio, March 10 /PRNewswire/ -- ChanTest, the leading expert in ion channels and GPCRs (G-protein coupled receptors) - key to drug discovery, development, and safety - will feature the latest in its expanding line of services and reagents at booth 3056 at the Society of Toxicology conference March 15-19, in Baltimore, Maryland. ChanTest's growing catalog, comprising 86 ion channel and 48 GPCR cell lines, can be arranged into panels for preclinical testing, consistent with the FDA and ICH S7A safety guidance, to assess a drug's risk for unintended cardiac (ICH S7B) and CNS (ICH S7A) effects. ChanTest also offers channel panels and high-throughput screening to assess the efficacy and safety of compounds as therapeutic targets for a number of diseases and disorders including cancer, cardiovascular, metabolic/gastrointestinal, pain/inflammation, psychiatric disorder, pulmonary/respiratory, and seizure/convulsion. ChanTest has validated these panels against the "gold standard" manual patch clamp assay to ensure that results from early screens will correlate with GLP study results that are required for IND submission.

For customers that prefer to do their own testing in house, ChanTest offers its catalog of validated ion channel and GPCR replicating cell lines for sale as reagents. Thirty-six division-arrested GPCR cell lines (EZCells (TM)) are also available.

"ChanTest is well known as the leader in preclinical cardiac safety testing. We were the first to prove hERG as the target for adverse cardiac events linked to Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and the pioneer in functional, cell-based ion channel testing to predict cardiac side effects produced by non-cardiac drugs," said ChanTest Chief Executive Officer, Dr. Arthur (Buzz) Brown, M.D., Ph.D. "As the knowledge base has expanded about the interrelated nature of ion channels and GPCRs in cell signaling, many of our customers have been requesting complementary GPCR cell lines and testing capabilities. Now, with our recent acquisition of Applied Cell Sciences, we can deliver ion channel and GPCR assays and cell lines - individually, or in combination to provide a complete safety profile. Because ChanTest specializes in both ion channels and GPCRs, scientists can count on ChanTest's experts to interpret what the results mean, not just report raw data as is typical of many CROs."

  • Seminar: Ion Channel Panels in Safety Assessment (March 17, 8:30 am, room 337) - Drug-induced ion channel dysfunction may result in diverse adverse reactions. This one-hour seminar will discuss how toxicity screening, secondary confirmatory screening, and selectivity profiling using ChanTest's Human Ion Channel Panels(TM) and automated patch clamp methods can facilitate decision-making in drug development.

About ChanTest - The Ion Channel/GPCR Company (www.chantest.com)

The leading experts in ion channels and GPCR (G-protein coupled receptors) - ChanTest and Applied Cell Sciences (ACS) - are now united to help global pharmaceutical and biotech customers speed the drug-discovery and development process, save time and money, and ultimately - to help make better, safer drugs. ChanTest offers integrated ion channel and GPCR services (both automated high-throughput and GLP), cell lines, membranes, and reagents that cover nearly half of the known drugable genome. Since its inception in 1998, ChanTest has tested more than 20,000 compounds for more than 500 pharmaceutical and biotech companies worldwide. ChanTest continues to expand its library of ion channel- and ion channel/GPCR-expressing cell lines - the most comprehensive in the world - with funding from the Ohio Department of Development's Third Frontier Program. Now, for the first time, customers can profile the efficacy and selectivity of drug leads against an extensive set of ion channels and GPCRs in functional, cell-based assays. ChanTest can screen drug leads, or large compound collections, against its entire catalog or against specific books in the catalog. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.


'/>"/>
SOURCE ChanTest
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
3. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
4. Other highlights in the September 11 JNCI
5. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. A New Interactive Consumer Experience Highlighting Successful Weight Loss Strategies is Coming to a Mall Near You
8. NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue
9. Launch of New Educational Campaign, Spread the Word - NOT the Flu!, Aims to Highlight Importance of Influenza Vaccination
10. Georgia Pecans Fit!: New Campaign Highlights Health Benefits, Recipes, Web Site
11. Highlights from the October 2007 Journal of the American Dietetic Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: